Cam Gallagher, Director at Zentalis Pharmaceuticals, Inc. (ZNTL), sold 19,000 shares at $78.24 ($1.4M) on 2022-01-05, disclosed to the SEC on 2022-01-05.
Open-market sale of $1.4M ZNTL by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $73.18 | 2,397 | $175K | 12.2% |
| 2 | $73.18 | 2,397 | $175K | 12.2% |
| 3 | $73.92 | 900 | $67K | 4.6% |
| 4 | $75.32 | 700 | $53K | 3.7% |
| 5 | $75.32 | 700 | $53K | 3.7% |
| 6 | $76.03 | 3,641 |
| $277K |
| 19.3% |
| 7 | $76.03 | 3,641 | $277K | 19.3% |
| 8 | $76.90 | 1,106 | $85K | 5.9% |
| 9 | $76.90 | 1,106 | $85K | 5.9% |
| 10 | $78.24 | 1,156 | $90K | 6.3% |
| 11 | $78.24 | 1,156 | $90K | 6.3% |
| 12 | $78.91 | 100 | $8K | 0.5% |
| Total | $75.54 avg | 19,000 | $1.4M | 100% |
| Filing → |
| ZNTL | SELL | 2024-02-12 | $13K | — | Filing → |
| ZNTL | SELL | 2024-02-05 | $267K | — | Filing → |
| ZNTL | SELL | 2023-05-31 | $1.5M | — | Filing → |